1. Pink Sheet
  2. >>Advanced Technologies

Gene Therapy AAV Vector Toxicities Get US FDA's Attention

 
• By Sue Sutter

Advisory committee will discuss five types of toxicity risks with adeno-associated virus vector-based gene therapy products at a two-day meeting in September, which follows some recent high-profile instances of adverse events that have delayed development programs.

Spotlight
US FDA is putting the spotlight on five types of toxicities with AAV gene therapy vectors. • Source: Alamy

A US Food and Drug Administration advisory committee will turn its attention to toxicity risks of adeno-associated virus vector-based gene therapy products at an upcoming two-day meeting.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

More from Advanced Technologies